Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0756
D

Pharmacist Failed to Identify Lapse in Anticoagulant Therapy

Charlotte, North Carolina Survey Completed on 10-27-2025

Penalty

Fine: $40,250
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility's Consultant Pharmacist failed to identify and address a significant lapse in anticoagulant therapy for a resident with a history of atrial fibrillation, type 2 diabetes, and pulmonary embolus. Eliquis, an anticoagulant, was discontinued for a surgical procedure and not resumed for approximately three months. During this period, the Consultant Pharmacist conducted monthly drug regimen reviews but did not recommend restarting the medication or document any follow-up regarding its discontinuation, despite reviewing the resident's medical chart, provider notes, and laboratory results. Interviews with the Consultant Pharmacist, Medical Director, Nurse Practitioner, and Director of Nursing confirmed that the omission of Eliquis from the resident's medication regimen was not identified or addressed in the pharmacy reviews. The Medical Director and facility leadership acknowledged that the monthly pharmacy reviews should have detected the prolonged discontinuation and brought it to the attention of the medical team.

An unhandled error has occurred. Reload 🗙